Surgical approach with vascular reconstruction after an objective response to neoadjuvant therapy with an EGFR tyrosine kinase inhibitor: clinical case.

CLINICAL CASES

https://doi.org/10.37469/0507-3758-2021-67-2-278-281

Published 06.05.2022

Evgeny Levchenko⁺⁻
Evgeny Slugin⁺⁻
Olga Lopushanskaya⁺⁻
Nikita Levchenko⁺⁻
Fedor Moiseenko⁺⁻
Evgeny Imyanitov⁺⁻
Nikolay Khandogin⁺⁻

Evgeny Levchenko

N.N. Petrov National Medical Research Center of Oncology

Evgeny Slugin

N.N. Petrov National Medical Research Center of Oncology

Olga Lopushanskaya

N.N. Petrov National Medical Research Center of Oncology

Nikita Levchenko

N.N. Petrov National Medical Research Center of Oncology

Fedor Moiseenko

Saint-Petersburg Clinical Scientificand Practical Center for Special Types of Medical Care (oncology-oriented)

Evgeny Imyanitov

N.N. Petrov National Medical Research Center of Oncology

Nikolay Khandogin

N.N. Petrov National Medical Research Center of Oncology

##article.numberofdownloads## 52

##article.numberofviews## 184

pdf (Русский)

Keywords

lung cancer
EGFR TKI
EGFR mutation
surgical treatment
targeted therapy

How to Cite

Levchenko, E., Slugin, E., Lopushanskaya, O., Levchenko, N., Moiseenko, F., Imyanitov, E., & Khandogin, N. (2022). Surgical approach with vascular reconstruction after an objective response to neoadjuvant therapy with an EGFR tyrosine kinase inhibitor: clinical case. Voprosy Onkologii, 67(2), 278–281. https://doi.org/10.37469/0507-3758-2021-67-2-278-281

Abstract

Tyrosine kinase inhibitors (TKIs) in the neoadjuvant mode and reconstructive techniques in surgical practice may expand the indications for the surgery in the treatment of patients with locally advanced non-small cell lung cancer (NSCLC) containing EGFR mutations.

https://doi.org/10.37469/0507-3758-2021-67-2-278-281

##article.numberofdownloads## 52

##article.numberofviews## 184

pdf (Русский)

References

Hishida T., Yoshida J., Aokage K. et al. Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases. Gen Thorac Cardiovasc Surg. 2016;7:429–33.

Levchenko E. et al. Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases. Onkologie 2009;32:674–677.

Gomez D.R., Blumenschein G.R. Jr, Lee J.J. et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung.

Sakanoue I. et al. Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib. J Thorac Dis. 2018 Mar;10(3):E170-E174.

Kappers I., Klomp H.M., Burgers J.A. et al. Neoadjuvant (induction) erlotinib response in stageIIIA non-small-cell lung cancer. J Clin Oncol. 2008;26:4205–7.

Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.

Hishida T., Nagai K., Mitsudomi T. et al. Japan clinical oncology group. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg. 2010;140:e69–71.

Takamochi K., Suzuki K., Sugimura H. et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer. 2007;58:149–55.

Shen H., Zhong X., Ge X.Q. et al. Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment. Clin Respir J. 2010;4:192–3.

Hashimoto K., Horinouchi H., Ohtsuka T. et al. Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer. Gen Thorac Cardiovasc Surg. 2012;60:851–4.

Marech I., Vacca A., Gnoni A. et al. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori. 2013;99:e241–4.

Lara-Guerra et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol. 2009 Dec 20;27(36):6229-36.

Schaake et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2012 Aug 1;30(22):2731-8.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Evgeniy Slugin, Evgeniy Levchenko, Evgeniy Imyanitov, Olga Lopushanskaya, The role of EGFR mutation testing in the choice for surgical tactics in NSCLC treatment , Voprosy onkologii : Vol. 67 No. 3 (2021)
Grigory Yanus, Tatyana Laidus, Kirill Zagorodnev, Aleksandr Martianov, Tatyana Sokolova, Svetlana Aleksakhina, Ekaterina Kuligina, Evgeny Imyanitov, Perspectives for the analysis of circulating tumor DNA in clinical oncology: achievements and unresolved issues , Voprosy onkologii : Vol. 67 No. 1 (2021)
Aleksandr S Martianov, Fedor Moiseenko, Albina Zhabina, Tatyana Sokolova, Sergey Beluhin, Tatiana Laidus, Maxim Kholmatov, Vladislav Turin, Nikita Volkov, Ekaterina Kuligina, Grigoiy Yanus, Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer , Voprosy onkologii : Vol. 67 No. 5 (2021)
Aglaya Iyevleva, Tatiana Gorodnova, Svetlana Aleksakhina, Elena Anisimova, Larisa Gigolaeva, Anna Sokolenko, Kirill Zagorodnev, Vadim Dmitriev, Igor Berlev, Piotr Krivorotko, Evgeny Imyanitov, Detection of TP53 mutations in plasma of ovarian cancer and breast cancer patients , Voprosy onkologii : Vol. 67 No. 2 (2021)
Fedor Moiseenko, Vladislav Tyurin, Nikita Levchenko, Yevgeniy Levchenko, Aglaya Ievleva, Yevgeniy Imyanitov, Natalya Mityushkina, DETECTION OF RESIDUAL LUNG CANCER CELLS BY PCR-BASED GENETIC TESTING FOR ROS1-TRANSLOCATION: CASE REPORT , Voprosy onkologii : Vol. 64 No. 3 (2018)
Fedor Moiseenko, Mariya Stepanova, Nikita Volkov, Albina Zhabina, A. Myslik, Anna Meldo, N. Rysev, D. Krylova, V. Klimenko, Andrey Bogdanov, Vladimir Moiseenko, PREDICTIVE VALUE OF THE DYNAMIC DETERMINATION OF CIRCULATING TUMOR DNA ON PFS IN PATIENTS WITH EGFR MUTATED NSCLC, WITH OSIMERTINIB THERAPY , Voprosy onkologii : Vol. 66 No. 2 (2020)
Yevgeniy Levchenko, VAN TIN, ChZhAN VEN, P. Kalinin, Tatyana Dubinina, Elvira Gumbatova, Nikita Levchenko, Lev Shevkunov, Andrey Mishchenko, Oleg Mamontov, Konstantin Senchik, Ya. Ulyanchenko, SUBSTANTIATION OF THE MODEL FOR CALCULATING THE INDIVIDUAL DOSE OF CYTOSTATICS USING CT VOLUMETRY FOR ISOLATED LUNG CHEMIOPERFUSION WITH METASTASECTOMY , Voprosy onkologii : Vol. 64 No. 3 (2018)
Evgeny V. Levchenko, Viktoria I. Shabinskaya, Nikita E. Levchenko, Alexander E. Mikhnin, Oleg Yu. Mamontov, Stepan M. Ergnyan, Nikolay Khandogin, Evgeny N. Slugin, Roman Yurin, Olga O. Lopushanskaya, Kirill D. Badaev, Outcomes after Bronchoplastic Sleeve Resection in Comparison with Pneumonectomy for Non-small Cell Lung Cancer , Voprosy onkologii : Vol. 70 No. 2 (2024)

<< < 1 2 3